Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation (train-IBD trial)
Anne Fennessy, Micheal Doyle, Anna Boland, Rachel Bourke, Anthony O'Connor, Department of Gastroenterology, Tallaght University Hospital, Dublin D24NR0A, Ireland
Author contributions: Fennessy A and O’Connor A designed the research study; Fennessy A, Doyle M, Boland A, Bourke R performed the research including recruitment and clinical assessment; Fennessy A and O’Connor A prepared the manuscript.
Institutional review board statement: The study was reviewed and approved by the SJH/TUH Joint Research Ethics Committee Institutional Review Board. Reference Number 2018/09/26.
Clinical trial registration statement: The registration identification number is 2018-003419-23.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at oconna12@tcd.ie.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anthony O'Connor, MBChB, MD, MRCP, MSc, Associate Professor, Doctor, Senior Lecturer, Department of Gastroenterology, Tallaght University Hospital, Belgard Rd, Dublin D24NR0A, Ireland. oconna12@tcd.ie
Received: September 9, 2024
Revised: January 16, 2025
Accepted: April 25, 2025
Published online: June 5, 2025
Processing time: 266 Days and 21.9 Hours
Revised: January 16, 2025
Accepted: April 25, 2025
Published online: June 5, 2025
Processing time: 266 Days and 21.9 Hours
Core Tip
Core Tip: A four-strain probiotic is well-tolerated in patients with inflammatory bowel disease (IBD) overlap and does not lead to adverse IBD related outcomes. Adequately powered studies are required to validate our observation of a trend towards better IBS outcomes in this group.